Ann Arbor, MI – September 30, 2004 – Please join us in congratulating our client STATPROBE, inc in their recent sale to i3 Research, which is owned by UnitedHealth Group (NYSE: UNH). Based in Ann Arbor, Michigan, with offices throughout the country, STATPROBE is one of the top independent CROs in the United States. Since 1988, STATPROBE has been one of the largest and most highly regarded providers of biostatistics and data management, and more recently had become recognized for their strength in clinical services, particularly Phase 4 services.

i3 Research brings a new level of focus to clinical research, specializing in oncology, central nervous system, and respiratory and infectious disease. With offices worldwide and capabilities in more than 45 countries, i3 provides a full, flexible suite of services including Project Management, Regulatory Services, Medical and Scientific Services, and Clinical Monitoring, all strategically integrated to create a seamless study. The Company also have services to support other critical aspects of clinical research. i3 Data Services provides industry-leading data management and biostatistics services across all therapeutic categories. i3 Pharma Resourcing provides high-quality pharmaceutical personnel supported by world-class service. And as an Ingenix company, i3 draws on the vast resources of UnitedHealth Group, a diversified health and well-being company.

Over the coming months, STATPROBE will merge with its i3 Data Services division—a leader in its own right, having recently distinguished itself as the first to bring Oracle® Clinical v4.5 to market—to form a dynamic new global company: i3 Statprobe

We were pleased to represent an industry leader and wonderful group at STATPROBE including Dr. Lora Schwab and Dr. Mark Becker (retired) the founders of STATPROBE, and Mark Harvill, Carl Haske, Terri Madison and Chris Stone. Lora and Mark H. are two of our favorite people in clinical research, and it was a pleasure to work with them to find such a great partner. Our hats are off to Glenn Bilawsky, the CEO of i3, and Lee Valenta, the CFO of parent company and health services leader Ingenix. Glenn and Lee were thorough, professional and friendly as they lead the UnitedHealth Group team. We think this deal really super-charges the biostatistics and data management skills of i3 Research, and supports their existing strengths in oncology, CNS and infectious disease, and brings added talents in the Phase 4 area. We look forward to seeing the great things that Glenn Bilawsky and Lora Schwab, the new President of i3 Statprobe, and their team will be able to achieve together.